Inhibitor Therapeutics, Inc. 8-K Filing
Ticker: INTI · Form: 8-K · Filed: Apr 1, 2026 · CIK: 0001042418
| Field | Detail |
|---|---|
| Company | Inhibitor Therapeutics, Inc. (INTI) |
| Form Type | 8-K |
| Filed Date | Apr 1, 2026 |
| Pages | 3 |
| Reading Time | 3 min |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Inhibitor Therapeutics, Inc. (ticker: INTI) to the SEC on Apr 1, 2026.
How long is this filing?
Inhibitor Therapeutics, Inc.'s 8-K filing is 3 pages with approximately 828 words. Estimated reading time is 3 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 828 words · 3 min read · ~3 pages · Grade level 11.9 · Accepted 2026-04-01 08:00:35
Filing Documents
- form8-k.htm (8-K) — 43KB
- ex99-1.htm (EX-99.1) — 15KB
- 0001493152-26-014517.txt ( ) — 219KB
- inti-20260401.xsd (EX-101.SCH) — 3KB
- inti-20260401_lab.xml (EX-101.LAB) — 33KB
- inti-20260401_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: April 1, 2026 INHIBITOR THERAPEUTICS, INC. By: /s/ Francis E. O'Donnell Name: Francis E. O'Donnell Title: Executive Chairman and CEO